Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.
Employees: 1-10
Investment Stage: Series B
Portfolio 58
| Date | Name | Website | Total Raised | Location |
| 07.08.2023 | Gracell Bi... | gracellbio.com | $250M | China, Jia... |
| 11.07.2023 | @Septerna_... | septerna.com | $290M | United Sta... |
| 17.10.2022 | Odyssey Th... | odysseytx.com | $487M | United Sta... |
| 27.08.2021 | Willow | onewillow.com | - | - |
| 17.08.2021 | Nuvalent | nuvalent.com | $187.23M | United Sta... |
| 17.08.2021 | Graphite B... | graphitebio.com | $195.75M | United Sta... |
| 17.08.2021 | Interius | interiusbio.com | $76M | United Sta... |
| 17.08.2021 | century_tx | centurytx.com | $410M | United Sta... |
| 17.08.2021 | Boundless ... | boundlessbio.com | $251.4M | United Sta... |
| 17.08.2021 | Ventyx Bio... | ventyxbio.com | $165M | United Sta... |
Show more
Mentions in press and media 14
| Date | Title | Description |
| 07.01.2025 | Jeito Capital's Bold Moves in Biopharma: A Strategic Investment Landscape | In the world of biopharma, where innovation is the lifeblood, Jeito Capital is making waves. This Paris-based private equity fund is not just dipping its toes; it’s diving deep into the ocean of clinical-stage biotech. With a recent investm... |
| 07.01.2025 | French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics | Paris-based Jeito Capital, a PE fund focused on biopharma innovation, has furthered its position as a player in global healthcare investment with two major contributions to clinical-stage biotech companies Aviceda Therapeutics and XyloCor T... |
| 07.01.2025 | Aviceda raises $207M series C to take geographic atrophy drug through phase 3 | Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease drug. The round was co-led by the healthcare funds Omega Funds and TCGX, wi... |
| 04.12.2024 | Maze Therapeutics Secures $115 Million to Revolutionize Kidney Disease Treatment | Maze Therapeutics, a beacon of innovation in the biopharmaceutical landscape, has successfully raised $115 million in a Series D financing round. This funding marks a significant milestone for the South San Francisco-based company, which is... |
| 03.12.2024 | Maze Therapeutics: $115 Million (Series D) Raised To Develop Precision Medicine | Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the ... |
| 03.12.2024 | Maze Therapeutics Raises $115M in Series D Financing | Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic disease... |
| 30.10.2024 | GlycoMimetics To Acquire Crescent Biopharma | GlycoMimetics (NASDAQ: GLYC), a Rockville, MD-based late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, acquired Crescent Biopharma, Inc., a biotechnology company advancing a pipeli... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 25.07.2024 | Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge** ** | ** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl... |
Show more